南方医科大学学报 ›› 2021, Vol. 41 ›› Issue (5): 736-746.doi: 10.12122/j.issn.1673-4254.2021.05.15

• • 上一篇    下一篇

靶向卵巢癌细胞的miR-16/多肽纳米递释系统的制备及其功能验证

黎权辉,岑柏宏,黄 文,陈佳扬,陈章浦,庞建新,付卫明,贺 帅,季爱民   

  • 出版日期:2021-05-20 发布日期:2021-06-11

Development and functional validation of a nano-delivery system of miR-16/polypeptide targeting ovarian cancer cells

  • Online:2021-05-20 Published:2021-06-11

摘要: 目的 研制增强顺铂敏感性的miR-16/多肽纳米递释系统,实现miRNA的卵巢癌靶向给药并验证其功能。方法 合成R9-SS-R9及cRGD-R9-SS-R9多肽,并与miR-16 mimic分子自组装形成纳米递释系统。利用琼脂糖凝胶电泳技术、粒径电位仪及透射电镜,测定纳米粒的稳定性、粒径、电位及形态等表征结果。利用CCK-8检测多肽对细胞的毒性。利用茎环qRT-PCR技 术、活细胞成像技术验证纳米粒的摄取效率及细胞内分布。利用流式细胞术及Western blot技术,验证纳米粒增强卵巢癌细胞顺铂敏感性的作用及其机制。结果 成功制备R9-SS-R9/miR-16、cRGD-R9-SS-R9/miR-16纳米粒,以5∶1的多肽/miRNA重量配比制得的纳米粒粒径在150 nm以下,分散指数小于0.1,电位约为40 mV,血清稳定性良好。多肽材料无明显的细胞毒性。miR-16/多肽纳米粒可被人卵巢癌细胞充分摄取并分布在细胞质中,且显著提高细胞内miR-16分子的表达水平(P<0.001),降低细胞中Bcl-2、Chk-1蛋白表达,实现miR-16的促细胞凋亡以及增强细胞对顺铂敏感性的作用。结论 成功制备了miR-16/多肽纳米递释系统,且该系统具有增强卵巢癌顺铂敏感性的功能。

关键词: miRNA;纳米递释系统;卵巢癌

Abstract: Objective To develop a nano-delivery system for targeted delivery of miR-16/polypeptide for enhancing cisplatin sensitivity of ovarian cancer. Methods R9- SS- R9 and cRGD- R9- SS- R9 peptides were synthesized and self- assembled with miR-16 molecules to form a nano-delivery system. The stability, particle size, potential and morphology of the nanoparticles were determined by agarose gel electrophoresis, particle size potentiometer and transmission electron microscopy. CCK-8 assay was used to assess the toxicity of the polypeptides in ovarian cancer cells. Stem loop qRT-PCR and living cell imaging were used to verify the uptake efficiency and intracellular distribution of the nanoparticles. Flow cytometry and Western blotting were performed to verify the effect of the nanoparticles for enhancing cisplatin sensitivity of ovarian cancer cells and explore the possible mechanism. Results R9-SS-R9/miR-16 and cRGD-R9-SS-R9/miR-16 nanoparticles were successfully prepared. The nanoparticles, with a particle size below 150 nm, a dispersity index less than 0.1 and a potential of about 40 mV, showed a good serum stability. The polypeptide material had no obvious cytotoxicity. The miR-16/polypeptide nanoparticles could be efficiently absorbed by human ovarian cancer cells and were distributed in the cytoplasm. The nanoparticles significantly increased the intracellular expression level of miR-16 (P<0.001) and decreased the expression of Bcl-2 and Chk-1 proteins in ovarian cancer cells, thus enabling miR-16 to promote apoptosis and enhance cisplatin sensitivity of the cells. Conclusion We successfully prepared a miR-16/polypeptide nano-delivery system for targeted delivery of miR-16 to ovarian cancer cells for enhancing cisplatin sensitivity of the cancer cells.

Key words: miRNA; nano-delivery system; ovarian cancer